AQST Stock Plunged 37% After FDA Setback; Securities Lawsuit Deadline Looms May 4

Aquestive Therapeutics Inc. ($AQST) investors have until May 4, 2026 to seek lead plaintiff status in a securities class action lawsuit alleging the company made materially false and misleading statements regarding its flagship drug Anaphylm's FDA approval timeline. The litigation, being managed by Faruqi & Faruqi, LLP, stems from a dramatic collapse in shareholder value following the company's disclosure of FDA deficiencies in its New Drug Application (NDA), resulting in a devastating 37% stock price decline in a single trading session.

The case centers on representations made by Aquestive Therapeutics regarding its confidence in securing FDA approval for Anaphylm by January 31, 2026—a critical milestone that the company publicly stated it expected to achieve. However, on January 9, 2026, the company announced that the FDA had identified significant deficiencies in the company's NDA submission, fundamentally undermining the regulatory trajectory investors had been promised. This abrupt reversal triggered immediate market punishment, with $AQST shares cratering as investors reassessed the company's clinical and commercial prospects.

Key Details of the Securities Action

The securities class action encompasses investors who purchased or acquired Aquestive Therapeutics securities during the period between June 16, 2025 and January 8, 2026—a span of approximately seven months during which the company was publicly promoting its anticipated FDA approval. This class period is critical, as it represents the window during which investors could have relied on the company's representations about Anaphylm's regulatory status.

Key facts and timeline of the case include:

• Stock performance impact: The announcement of FDA deficiencies on January 9, 2026 triggered a 37% single-day stock decline, erasing substantial shareholder value
• Class period: June 16, 2025 through January 8, 2026
• Deadline for action: May 4, 2026 for investors to seek lead plaintiff status
• Core allegation: False and misleading statements regarding FDA approval timeline and regulatory confidence
• Affected security: Common stock of Aquestive Therapeutics Inc. ($AQST)

Investors who purchased shares during this period are eligible to participate in the litigation and potentially recover damages if the case succeeds. The lead plaintiff role is particularly important, as the designated lead plaintiff typically represents the broader class and plays a significant role in overseeing the litigation strategy.

Market Context and Competitive Landscape

The collapse of Aquestive Therapeutics' regulatory narrative represents a cautionary tale in the pharmaceutical sector, where clinical-stage and development-focused companies face intense scrutiny over their FDA interactions and approval prospects. For small-cap biotech companies like $AQST, regulatory milestones often represent make-or-break moments that can determine long-term viability and shareholder returns.

Anaphylm, positioned as Aquestive's primary asset, appears to be a critical program in the company's pipeline. The failure to achieve anticipated FDA approval by the promised timeline raises fundamental questions about:

• Regulatory execution: Whether Aquestive adequately prepared its NDA submission
• Clinical data sufficiency: Whether the underlying clinical evidence supported the regulatory strategy
• Management credibility: Whether company guidance on regulatory timelines was appropriately cautious and evidence-based
• Investor communication: Whether investors received adequate disclosure of regulatory risks

In the biotech sector, regulatory disappointments are not uncommon, but publicly projecting confidence in specific approval timelines—particularly month-specific deadlines like "January 31, 2026"—represents a higher standard of accountability. When such projections prove inaccurate due to FDA feedback, securities litigation often follows, particularly if share prices decline sharply.

The small-cap biotech space has faced considerable scrutiny in recent years regarding disclosure practices and the accuracy of regulatory guidance. Investors in early-stage pharmaceutical companies have become increasingly sophisticated in distinguishing between preliminary optimism and substantiated regulatory projections, making cases like the Aquestive action potentially significant for establishing standards around FDA-related disclosures.

Investor Implications and Forward-Looking Considerations

This case carries several important implications for shareholders and investors evaluating biotech investments:

For affected shareholders: Participating in the class action represents a potential avenue to recover losses stemming from the alleged misstatements. Successful securities litigation in the pharmaceutical space can yield substantial settlements or judgments, though outcomes vary considerably based on evidence strength, defendant resources, and insurance coverage.

For regulatory transparency standards: The litigation may reinforce expectations that public companies disclose material uncertainties regarding FDA interactions and regulatory timelines. Companies cannot simply assert confidence in specific approval dates without substantiating the basis for such projections.

For biotech investors broadly: This case exemplifies execution risk in clinical-stage pharmaceutical development. Even well-capitalized companies with promising candidates can encounter unexpected regulatory obstacles. Investors should scrutinize how management communicates regulatory prospects and whether guidance reflects conservative assumptions about FDA feedback.

For $AQST shareholders: Beyond the litigation, investors must evaluate whether Aquestive Therapeutics can recover operationally and commercially. The company will need to:

• Address FDA deficiencies and resubmit an amended NDA
• Restore credibility with investors regarding regulatory projections
• Assess whether Anaphylm remains viable in its current form or requires modification
• Evaluate whether the stock's dramatic decline reflects fair repricing or potential recovery opportunity

The May 4, 2026 lead plaintiff deadline represents a significant date for affected investors, but the broader litigation could extend years into the future. Securities class actions in the pharmaceutical sector frequently settle during preliminary motion stages or eventually proceed to trial, with outcomes typically determined by the strength of evidence regarding what management knew about FDA feedback and when.

Closing Perspective

The Aquestive Therapeutics securities action underscores the substantial risks facing investors in small-cap biotech companies dependent on regulatory approval for commercialization. While the pharmaceutical sector's regulatory pathway is inherently uncertain, publicly stated confidence in specific approval timelines creates legal and fiduciary obligations that companies cannot easily dismiss.

For investors who purchased $AQST shares between June and January and have not yet consulted legal counsel regarding the class action, the May 4, 2026 deadline for seeking lead plaintiff status should prompt immediate action. The litigation's ultimate outcome will likely turn on detailed discovery regarding management's knowledge of FDA concerns and the timing of that knowledge relative to investor communications.

Beyond the litigation itself, this episode reinforces a fundamental principle for biotech investors: distinguish between regulatory optimism and regulatory certainty, scrutinize the basis for company-provided timelines, and recognize that even experienced management teams can encounter unexpected regulatory hurdles. For Aquestive Therapeutics, the path forward requires both addressing FDA deficiencies and rebuilding shareholder confidence in management's regulatory judgment.